Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials – CNA
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Advertisement
Advertisement
Sinopharm is testing the potential vaccin…
-
General10 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Business18 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News22 hours agoResilience features in Sunshine Coast Open House
-
Noosa News17 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025